US FDA hits Cephalon with complete response letter for jet lag drug
This article was originally published in Scrip
The US FDA has hit Cephalon with a complete response letter over its sNDA for Nuvigil (armodafinil) for the treatment of patients with excessive sleepiness associated with jet lag resulting from eastbound travel, raising queries over the data included in the application.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.